These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8817542)

  • 21. Neuropeptide Y depresses GABA-mediated calcium transients in developing suprachiasmatic nucleus neurons: a novel form of calcium long-term depression.
    Obrietan K; van den Pol AN
    J Neurosci; 1996 May; 16(10):3521-33. PubMed ID: 8627385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circadian phase shifts to neuropeptide Y In vitro: cellular communication and signal transduction.
    Biello SM; Golombek DA; Schak KM; Harrington ME
    J Neurosci; 1997 Nov; 17(21):8468-75. PubMed ID: 9334419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neuropeptide Y applied in vitro can block the phase shifts induced by light in vivo.
    Yannielli PC; Harrington ME
    Neuroreport; 2000 May; 11(7):1587-91. PubMed ID: 10841381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of the phase shifting effects of gastrin releasing peptide when microinjected into the suprachiasmatic region.
    Albers HE; Gillespie CF; Babagbemi TO; Huhman KL
    Neurosci Lett; 1995 May; 191(1-2):63-6. PubMed ID: 7659293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuropeptide Y blocks light-induced phase advances but not delays of the circadian activity rhythm in hamsters.
    Weber ET; Rea MA
    Neurosci Lett; 1997 Aug; 231(3):159-62. PubMed ID: 9300646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects.
    Heilig M; McLeod S; Brot M; Heinrichs SC; Menzaghi F; Koob GF; Britton KT
    Neuropsychopharmacology; 1993 Jun; 8(4):357-63. PubMed ID: 8099792
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neuropeptide Y does not reset the circadian clock in NPY Y2-/- mice.
    Soscia SJ; Harrington ME
    Neurosci Lett; 2005 Jan; 373(3):175-8. PubMed ID: 15619538
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Short-term exposure to constant light promotes strong circadian phase-resetting responses to nonphotic stimuli in Syrian hamsters.
    Knoch ME; Gobes SM; Pavlovska I; Su C; Mistlberger RE; Glass JD
    Eur J Neurosci; 2004 May; 19(10):2779-90. PubMed ID: 15147311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neuropeptide Y produces anxiety via Y2-type receptors.
    Nakajima M; Inui A; Asakawa A; Momose K; Ueno N; Teranishi A; Baba S; Kasuga M
    Peptides; 1998; 19(2):359-63. PubMed ID: 9493869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropeptide Y 16-36 inhibits mucociliary activity but does not affect blood flow in the rabbit maxillary sinus in vivo.
    Cervin A
    Regul Pept; 1992 Jun; 39(2-3):237-46. PubMed ID: 1438973
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuropeptide Y stimulates bile secretion via Y1 receptor in the left dorsal vagal complex in rats.
    Yoneda M; Nakamura K; Yokohama S; Tamori K; Sato Y; Aso K; Aoshima M; Kono T; Makino I
    Hepatology; 1998 Sep; 28(3):670-6. PubMed ID: 9731557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuropeptide Y phase advances the in vitro hamster circadian clock during the subjective day with no effect on phase during the subjective night.
    Harrington ME; Schak KM
    Can J Physiol Pharmacol; 2000 Feb; 78(2):87-92. PubMed ID: 10737670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropeptide Y blocks serotonergic phase shifts of the suprachiasmatic circadian clock in vitro.
    Prosser RA
    Brain Res; 1998 Oct; 808(1):31-41. PubMed ID: 9795117
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuropeptide Y and N-methyl-D-aspartic acid interact within the suprachiasmatic nuclei to alter circadian phase.
    Gamble KL; Novak CM; Albers HE
    Neuroscience; 2004; 126(3):559-65. PubMed ID: 15183505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neuropeptide Y blocks GABAB-induced phase-shifts of the suprachiasmatic circadian clock in vitro.
    Biggs KR; Prosser RA
    Brain Res; 1999 Mar; 821(2):461-6. PubMed ID: 10064833
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropeptide Y suppresses epileptiform activity in rat frontal cortex and hippocampus in vitro via different NPY receptor subtypes.
    Bijak M
    Neurosci Lett; 1999 Jun; 268(3):115-8. PubMed ID: 10406018
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of neuropeptide Y-induced feeding: dissociation of Y1 and Y2 receptor effects on natural meal patterns.
    Leibowitz SF; Alexander JT
    Peptides; 1991; 12(6):1251-60. PubMed ID: 1667688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuropeptide Y-mediated long-term depression of excitatory activity in suprachiasmatic nucleus neurons.
    van den Pol AN; Obrietan K; Chen G; Belousov AB
    J Neurosci; 1996 Sep; 16(18):5883-95. PubMed ID: 8795640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Depressor effect of intrathecal neuropeptide Y (NPY) Is mediated by Y2 subtype of NPY receptors.
    Chen X; Westfall TC
    J Cardiovasc Pharmacol; 1993 May; 21(5):720-4. PubMed ID: 7685440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of neuropeptide Y and agonists selective for neuropeptide Y receptor sub-types on arterioles of the guinea-pig small intestine and the rat brain.
    Xia J; Neild TO; Kotecha N
    Br J Pharmacol; 1992 Nov; 107(3):771-6. PubMed ID: 1472974
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.